KMDA.US Kamada

Healthcare Biotechnology USA Stocks
8.09 USD
Close of Nov 15, 2026
6.28 8.96
Market cap
USD 467M
P/E
21.3x
P/B
1.74x
ROE
10.6%
Dividend yield
2.67%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KMDA.US undervalued?

Graham number
Price8.09
Graham value6.31
Premium28.2%

KMDA.US trades 28.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kamada fundamental analysis

No fundamental analysis for Kamada yet.

Kamada stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and p…

Full company profile